Literature DB >> 1593222

Nonopsonic uptake of Mycobacterium avium complex by human monocytes and alveolar macrophages.

J A Roecklein1, R P Swartz, H Yeager.   

Abstract

The uptake of Mycobacterium avium complex (MAC) microorganisms by human peripheral blood monocytes (PBMs) and alveolar macrophages (AMs) is not well understood. We have previously shown, under opsonic conditions, that humoral factors are important in mediating the uptake of MAC by PBMs. However, the receptor-ligand interactions occurring under nonopsonic conditions remain unclear. We compared the uptake of untreated human PBMs and AMs in a serum-free medium with phagocytes treated to remove surface receptors. Removal of complement receptors CR1 and CR3, the Fc receptor (FcR), and the transferrin receptor (TfR) resulted in significantly lower levels of MAC uptake in serum-free medium by both PBMs and AMs. The addition of barley beta-glucan or mannan from Saccharomyces cerevisiae inhibited MAC uptake by untreated phagocytes in a dose-dependent manner. MAC uptake by PBMs or AMs was never completely abrogated by combining treatments (removal of CR1, CR3, FcR, and TfR and adding mannan or beta-glucan), indicating still-unknown mechanisms of uptake under nonopsonic conditions. We conclude that CR1, CR3, FcR, TfR, the mannose receptor, and possibly a separate beta-glucan-inhibitable receptor all may be involved in nonopsonic uptake of MAC by both PBMs and AMs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1593222

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  18 in total

1.  Fibronectin facilitates Mycobacterium tuberculosis attachment to murine alveolar macrophages.

Authors:  Rajamouli Pasula; Paul Wisniowski; William J Martin
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

2.  Role of CD40 ligand in Mycobacterium avium infection.

Authors:  T Hayashi; S P Rao; P R Meylan; R S Kornbluth; A Catanzaro
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

3.  Mycobacterial protein HbhA binds human complement component C3.

Authors:  S L Mueller-Ortiz; A R Wanger; S J Norris
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

4.  Mycobacterium avium-intracellulare contamination of mammalian cell cultures.

Authors:  I H Lelong-Rebel; Y Piemont; M Fabre; G Rebel
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-10-15       Impact factor: 2.416

5.  The glycan-rich outer layer of the cell wall of Mycobacterium tuberculosis acts as an antiphagocytic capsule limiting the association of the bacterium with macrophages.

Authors:  Richard W Stokes; Raymond Norris-Jones; Donald E Brooks; Terry J Beveridge; Dan Doxsee; Lisa M Thorson
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

6.  Virulence-related Mycobacterium avium subsp hominissuis MAV_2928 gene is associated with vacuole remodeling in macrophages.

Authors:  Samradhni S Jha; Lia Danelishvili; Dirk Wagner; Jörg Maser; Yong-jun Li; Ivana Moric; Steven Vogt; Yoshitaka Yamazaki; Barry Lai; Luiz E Bermudez
Journal:  BMC Microbiol       Date:  2010-04-01       Impact factor: 3.605

7.  Enhancement of macrophage candidacidal activity by interferon-gamma. Increased phagocytosis, killing, and calcium signal mediated by a decreased number of mannose receptors.

Authors:  L Maródi; S Schreiber; D C Anderson; R P MacDermott; H M Korchak; R B Johnston
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

Review 8.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

9.  Induction of Mycobacterium avium gene expression following phagocytosis by human macrophages.

Authors:  G Plum; J E Clark-Curtiss
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

Review 10.  Tactics of Mycobacterium avium subsp. paratuberculosis for intracellular survival in mononuclear phagocytes.

Authors:  Seng Ryong Woo; Charles J Czuprynski
Journal:  J Vet Sci       Date:  2008-03       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.